Li 2005

Methods	A single‐centre, randomised controlled trial (China) Baseline period: unclear Treatment phase: 8 weeks
Participants	67 patients with epilepsy and depression (meeting CCMD‐3 criteria for depression and HAMD‐21 score >18)
Interventions	Paroxetine (n = 33): 17 males, 16 females aged 14 to 62 years 10 mg to 40 mg/day Doxepin (n = 34): 15 males, 19 females, aged 16 to 59 years, dose 25 mg/day titrated up according to response (mean dose 100 mg)
Outcomes	1) Change in depression scores (HAMD‐21) from baseline 2) Adverse events
Notes	3 patients discontinued study in doxepin arm because of adverse events, with 31 patients analysed for this treatment arm
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Randomisation carried out by flipping of a coin
Allocation concealment (selection bias)	Unclear risk	No details available regarding methods of allocation concealment
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Patients blinded
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Outcome assessor blinded
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Missing data reported, ITT not employed
Selective reporting (reporting bias)	High risk	Adverse events not reported in results. Rated as letter E in ORBIT tool.
Other bias	Unclear risk	Insufficient details in report to judge the influence of other bias
Confounding variables	Low risk	NA